# 2026-09292: Uncle Sam Licenses Brake-Free T Cells to Battle Cancer and Infections

2026-09292, Government Owned Inventions Available for License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-05-11, effective 2026-05-11; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09292
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09292
- Title: Government Owned Inventions Available for License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 25584
- Published: 2026-05-11
- Effective: 2026-05-11
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Uncle Sam Licenses Brake-Free T Cells to Battle Cancer and Infections

## Summary

The government has a cool new discovery that makes certain immune cells, called T cells, better at fighting cancer and other diseases by turning off some ‘brakes’ inside them. This could lead to stronger, smarter treatments for cancer, infections, and autoimmune problems. Companies interested in licensing this tech should act soon to help bring these powerful therapies to patients and the market.

## Abstract

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.

## Effects PRIA read

- Government tech available for licensing: benefit, medium. The National Institutes of Health is offering a government-owned discovery (NICHD Reference Number E-004-2024) for license to developers interested in T‑cell immunotherapy. Companies and researchers can pursue licensing to develop therapeutics that target the inhibitory proteins SIT1, LAX1, or TRAT…
- Patent protection already filed: benefit, medium. The NIH reports a Patent Cooperation Treaty (PCT) application was filed on January 24, 2025, and the intellectual property rights have been assigned to the U.S. Government. Potential licensees will negotiate license rights against that government-held IP.
- Technology at pre-clinical stage: mixed, medium. The discovery is at the pre-clinical stage with in vivo validation underway. That means developers would need to invest in further pre-clinical and clinical work to bring a therapy to market.
- Potential new therapies for major diseases: benefit, low. Researchers report that targeting SIT1, LAX1, or TRAT1 could improve T‑cell therapies to treat cancer, infectious diseases, and autoimmune diseases. The notice highlights potential therapeutic benefits such as stronger tumor‑killing activity and improved immune responses.

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2026-09292 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/11/2026-09292/government-owned-inventions-available-for-license-enhanced-tumor-reactivity-of-t-cells-lacking-sit1)
- [2026-09292 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-11/pdf/2026-09292.pdf)

## Related
- [Previous: 2026-09291, Notice of Public Meeting of the Virginia Advisory Committee to the U.S. Commiss…](https://policyrisk.com/federal-register/2026-09291)
- [Next: 2026-09294, Ampersand Hollow Dam Hydro, LLC; Notice of Authorization for Continued Project…](https://policyrisk.com/federal-register/2026-09294)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09292 (as of 2026-06-08).
